Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)

• Published in: Memórias do Instituto Oswaldo Cruz Vol. 112; no. 12; pp. 838 - 843
• Main Authors: Brahim, Lucia Regina, Valete-Rosalino, Cláudia Maria, Antônio, Liliane de Fátima, Pimentel, Maria Inês Fernandes, Lyra, Marcelo Rosandiski, Paes, Luiz Eduardo de Carvalho, Costa, Ananda Dutra da, Vieira, Iracema Forni, Dias, Cristina Maria Giordano, Duque, Maria Cristina de Oliveira, Marzochi, Mauro Celio de Almeida, Schubach, Armando de Oliveira
• Format: Journal Article
• Language: English
• Published: Brazil Instituto Oswaldo Cruz, Ministério da Saúde 01.12.2017; Fundação Oswaldo Cruz (FIOCRUZ)
• Subjects: American tegumentary leishmaniasis; lethality; meglumine antimoniate; mucosal leishmaniasis; PARASITOLOGY; relapse; TROPICAL MEDICINE; American tegumentary leishmaniasis; meglumine antimoniate; mucosal leishmaniasis; relapse; lethality

American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at healing the lesions and preventing the development of the late mucosal form. Systemic meglumine antimoniate (MA) therapy with 10-20 mg S...